FindTrial
Sign In

Tezepelumab-placebo

DRUG3 trials

Sponsors

AstraZeneca AB

Conditions

Chronic Obstructive Pulmonary Disease (COPD)Chronic obstructive pulmonary disease (COPD)Eosinophilic esophagitis (EoE) is a rarechronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus

Phase 3

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING)
Active, not recruitingCTIS2023-504277-20-00
AstraZeneca ABchronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus, Eosinophilic esophagitis (EoE) is a rare
Start: 2023-01-30Target: 211Updated: 2026-01-22
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (EMBARK)
RecruitingCTIS2024-517458-90-00
AstraZeneca ABChronic obstructive pulmonary disease (COPD)
Start: 2025-06-06Target: 187Updated: 2025-12-04
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (JOURNEY)
RecruitingCTIS2024-517457-27-00
AstraZeneca ABChronic Obstructive Pulmonary Disease (COPD)
Start: 2025-06-04Target: 293Updated: 2026-01-14